The alliance is backloaded, with $21.5 million paid upfront and Insilico also in line for mid-single to up to low double-digit tiered royalties for any products developed, but it is comfortably the Chinese company’s largest deal to date.
“This collaboration will leverage our complementary capabilities, as well as the co-location of our scientific teams, to boost the drug discovery efforts of the Sanofi Institute for Biomedical Research (SIBR), Sanofi’s R&D centre in China,” said Changchun Xiao, head of China research at Sanofi.
